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Abstract
Chronic pain is a common debilitating condition in the United States. The
treatment of chronic pain is complex and can sometimes lead to addiction of opioid
medications. However, there is another, more natural option in the treatment of chronic
pain—the use of CBD, cannabidiol which is a phytocannabinoid from hemp and
marijuana, for the treatment and management of chronic pain. While CBD is labeled a
schedule I drug by the Food and Drug Administration in the United States, there is
evidence that CBD can make an impact on the severity of pain, the amount of opioids in
use, and the overall quality of life of the patient. Through the education on the use of
CBD in the treatment and management of pain, there will be more knowledge about the
effectiveness of CBD as an alternative option in the treatment of chronic pain. This
study focuses on the effects of an educational session about CBD on the treatment and
management on the knowledge of college students. The hypothesis being tested is that
knowledge about using CBD for treatment and management of chronic pain will be
increased following the educational session. A pre-test and post-test method of
evaluation was used in the study. With a sample of 23 participants, the results indicated
that there was a statistically significant increase from the scores of the pre-test
compared to the post-test potentially due to the educational session.
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The Treatment and Management of Chronic Pain using CBD
Introduction
With laws passed in the 1970s, plants and substances that have been used as
healing agents for many years were suddenly considered dangerous and damaging to
the human body (Hande, 2019). Recently, there has been more discussion surrounding
the use of some natural chemicals in the treatment of various medical conditions.
However, there is little information taught to the general public on these chemicals, and
the general public is required to take information at face value because any in-depth
discussion surrounding these substances is done in legal terms only. These chemicals
could be useful in medical treatments. One of the most widely discussed chemicals is
Cannabinoids (CBD), derived from both Cannabis and Hemp.
Background and Significance
Chronic pain is defined as “persistent or recurring pain that is often difficult to
treat. [It] Includes any pain lasting longer than 3 to 6 months, pain lasting longer than 1
month after healing of an acute injury, or pain that accompanies a nonhealing tissue
injury” (Lilley, Collins, & Snyder, 2020, p. 136). The nature of chronic pain makes it
increasingly difficult to both diagnose and treat the symptoms that are associated.
Because of the difficulty in diagnosing and treating chronic pain, chronic pain has
become a category of illness so large as to surpass the numbers of people plagued by
both heart disease and cancer: “Chronic pain affects between 50 and 116 million
American adults, a staggering number that surpasses those affected by heart disease,
cancer, and diabetes combined” (Argueta, Gupta, Sagi, & Ventura, 2020, p. 2). This
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means that, more than likely, every single person in the United States knows someone
who suffers from some type of chronic pain.
Not only is chronic pain a complex and difficult medical diagnosis to understand,
one of the primary ways to treat the pain is with opioids, leading to an increased amount
of opioid medications that are being prescribed in the United States. Overprescribing
opioid medications leds to an increase of the opioid epidemic that the United States is
facing (Argueta et al., 2020). Not only are opioid medications some of the first-line
medications that are prescribed for the treatment of chronic pain, but there is evidence
that patients do not always respond to opioid medications with the desired therapeutic
effects, necessitating an increase in the volume of opioid medications that are
prescribed and attempted before potentially finding a therapeutic effect (Capano,
Weaver, & Burkman, 2020). These patients often become tolerant and addicted to the
pain medications that are prescribed for the treatment of pain, which makes finding
alternative treatments incredibly important to keep these patients comfortable and
functioning (Capano et al., 2020). Contrary to typical medical prescribing practice and
pharmaceutical companies’ advertising, though, pharmaceuticals are not the only option
when treating patients with chronic pain; however, the other options are more
controversial and their effectiveness is still being debated.
There is evidence to support that cannabidiol (CBD) oil is an effective treatment
for chronic pain in adults; however, not enough evidence was found to support it as a
standalone treatment (Collins, 2020). There is significant evidence to support the use of
cannabidiols in treatment of chronic pain and spasticity (VanDolah, Bauer, & Mauck,
2019). Cannabidiols interact with the endocannabinoid system within the body, which
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serves the purpose of regulating stress/harm in the body, helping to monitor
homeostasis and a multitude of other factors (Corroon & Felice, 2019). Generally, the
endocannabinoid system has signaling molecules that interact with the system to
release the neurotransmitters that help regulate the stress response and homeostasis
(Corroon & Felice, 2019). However, the endocannabinoid system reacts to exogenous
molecules that contain phytocannabinoids; these can be an important addition to the
human body as some individuals do not create enough phytocannabinoids to maintain
an adequate level in the body (Germano, 2018). Phytocannabanoids are found in more
than just cannabidiol from hemp or marijuana. For example, “carrots, hops, chocolate,
echinacea, cloves, pepper, thyme, and rosemary all have very minute levels of
phytocannabinoids” (Germano, 2018, p. 23). The endocannabinoid system has two
primary receptors, CB1 and CB2, and CBD molecules bind with both in order to have
effects on different physiological processes and disorders (Misuraca, 2020). This
connection makes it possible for CBD to have a positive impact on the human body and
help to control pain.
If more doctors, nurses, and patients are educated about the endocannabinoid
system, phytocannabinoids—including cannabidiol from hemp and marijuana—could be
an additional option for the treatment of chronic pain. Cannabinoids have been shown to
both decrease the amount of pain that chronic pain patients are experiencing and also
reduce the number of opioids patients are taking (Capano et al., 2020). Reducing the
number of opioids that a patient is taking, while still decreasing the patient’s pain, allows
the overall number of opioids being prescribed to be reduced, thus, also potentially
impacting the opioid crisis.
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Purpose
With the rising opioid epidemic, there is a need to find alternative therapies that
can treat patients by adequately decreasing the amount of pain that they are
experiencing, but that also do not require the continual and increased risk of opioid
addiction. Better education can inform the general population about the risks of opioids
in treating chronic pain as well as about the alternative therapies available to them; such
education would also benefit doctors, nurses, and their patients by making them more
aware of the entire spectrum of therapies available. The purpose of this study is to
provide education on the benefits of using CBD therapy in order to treat and manage
chronic pain and evaluate the effectiveness of that education. Cannabidiol therapy has
been shown to decrease the amount of pain patients are experiencing, while
simultaneously decreasing the amount of opioid medications the patients need to take.
Research Question
The research question for this study is as follows: Is there an increase in
knowledge about the use of CBD to treat and manage chronic pain after an educational
session explaining the use of CBD? By hosting an educational session, it is
hypothesized that knowledge about using CBD for treatment and management of
chronic pain will be increased. The increased knowledge about using CBD will allow the
population to be informed about the true uses of CBD as well as the research that has
already been done to support and disprove what CBD can actually do for a patient in
pain.
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Review of Literature
Rates of Chronic Pain
Chronic pain affects between 50 to 160 million American adults, a number which
is more than heart disease, cancer, and diabetes combined (Argueta et al., 2020).
Chronic pain is a major cause of disability throughout the world “with a prevalence rate
of 15% to 30% in the general adult population, and more than 500 billion dollars annual
costs in the United States” (Capano et al., 2020, p. 56). Additionally, a majority of
people who report having chronic pain say that they have not found a satisfactory
pharmaceutical plan to limit the pain they experience (Capano et al., 2020). One cause
of chronic pain, for example, is migraine headaches—which affect approximately 18%
of women and 6% of men in the United States and Europe (Baron, 2018). Chronic pain
is a problem that plagues the country and that many individuals deal with on a daily
basis. However, a majority of people who report having chronic pain do not feel like the
pain is controlled enough for normal daily functioning.
Clinical Implications
There have been several studies completed to determine whether there is
significant data to determine CBD’s usefulness as an option in treating chronic pain.
CBD has been tested to determine its impact on three key components of the lives of
chronic pain patients: reduced pain, increased quality of life, and decreased addiction to
opioids. These three areas have been assessed as determining factors for the use of
CBD in chronic pain and whether it would make an impact on the lives of these patients.
The first component that CBD has been tested for is in the reduction of pain in
patients with chronic pain. Since the clinical trials on CBD have begun, the impact of
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CBD on pain has ranged from placebo-effect to highly effective, this range of results
coming from trials done as part of well-designed randomized, double-blinded studies
(Argueta et al., 2020). In cases of specific chronic pain—patients with nerve pain and
fibromyalgia—CBD seems to have significantly decreased pain on a visual analog
scale, a pain scale that allows patients to place their pain on a visual scale (Argueta et
al., 2020). Another study shows that CBD is an effective treatment for pain, but there
needs to be more studies and research done to understand the extent to which CBD
helps patients who report they have chronic pain. Additionally, this study reports that,
while there is evidence to support the use of CBD products in patients with chronic pain,
there is not enough evidence to support CBD being a standalone treatment for pain
(Collins, 2020). In a study conducted specifically for patients that experience headache
pain and chronic pain related to migraines, there was significant evidence to support the
use of CBD in these patients. These studies conducted used a specific synthetic
cannabinoid, nabilone 0.5 mg, which was “superior in reducing daily analgesic intake,
pain intensity, level of medication dependence, and improved quality of life in these
patients” (Baron, 2018, p. 1141). Lastly, there were numerous preclinical studies that
have shown the beneficial effects of cannabinoids in treating acute pain, chronic pain,
and neuropathic pain (Corroon & Felice, 2019). However, in patients with generalized
pain, there seemed to be less of an impact on reduced pain and more of an impact on
the increase of quality of life (Argueta et al., 2020). These different articles show that
CBD can be used to treat different types of pain, including chronic pain, in an effective
manner.
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The second major component that was examined when determining whether
CBD has an effect on the lives of patients with chronic pain is whether it has a positive
impact on the patients’ quality of life. One study summarized multiple clinical trials that
were performed to verify the use of CBD and concluded that there was an improved
functionality and quality of life in patients who began using CBD as an adjunct therapy
to their chronic pain treatment (Collins, 2020). Another study found similar results:
“Eighty-nine (94%) of the hemp CBD users reported improved quality of life outcomes
on subjective, open-ended questions” (Capano et al., 2020, p. 58). This study
concluded that there were two main areas that were improved—specifically, quality of
life related to pain and sleep (Capano et al., 2020). Of the studies conducted to
specifically ascertain CBD’s impact on the quality of life, the majority of the studies
stated that using CBD does improve aspects of life.
The final research area that was explored in patients with chronic pain using
CBD was whether it decreased the number of opioid medications and addiction to
opioids. Cannabidiol has been shown to reduce, at least to an extent, the amount of
pain that chronic pain patients experience, but studies have also shown that CBD has
less of an abuse potential and minimizes the risk of opioid abuse by presenting another
option to control pain (VanDolah et al., 2019). Another article states that there is
evidence to support the use of cannabidiol in the treatment of addiction when treating
“opioids, cannabis, tobacco, and stimulants” (Poorman, 2019, p. 1). Another study
examines evidence to support the use of CBD as a pain reliever sufficient enough to
replace opioids as a treatment option, thus lowering the number of opioids a patient
could be taking (Tweed, 2019). In fact, CBD does not contain the psychoactive, and
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possibly dangerous and addictive, ingredient that cannabis does, making CBD a safe
alternative to the opioids (Tweed, 2019). Capano et al.’s study showed that patients felt
like they could reduce the number of opioid medications/doses they were taking: “Fifty
of the 94 (53.2%) participants using the CBD hemp extract were able to reduce opioid
medications at week 8. Additional reductions in polypharmacy on the medication receipt
were noted” (Capano et al., 2020, p. 58). If CBD is successful in treating chronic pain
and improving patient’s quality of life, there would be less need for patients to take
higher abuse-potential drugs that often lead to withdrawal symptoms and addiction.
Endocannabinoid System
As with all medications that work in human bodies, CBD responds to a system
that interacts with receptors in human bodies to help regulate the system. The system
that CBD interacts with is called the endocannabinoid system. This system “evolved as
a stress/harm regulation network that functions to restore homeostasis following cellular
stressors” (Corroon & Felice, 2019, p. 6). Endocannabinoids are the signaling
molecules in this system and are “fatty-acid neurotransmitters that safeguard body
systems by coordination and fine-tuning intracellular biochemistry and intercellular
communication across all physiological systems without exception” (Corroon & Felice,
2019, p. 7). Even though this system is not taught about nearly as much as other body
systems, the functioning of this system is imperative for the body to work correctly and,
if the body does not produce enough endogenous endocannabinoids, there could be
negative effects. For example, “endocannabinoid deficiency states are associated with
migraines, fibromyalgia, irritable bowel syndrome, and inflammatory and neurological
conditions” (Germano, 2018, p. 22). CBD is one of the exogenous phytocannabinoids
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that interacts with the CB receptors in the system to help maintain a balance and
restore homeostasis (Capano et al., 2020). Understanding the endocannabinoid system
is important to the understanding and use of CBD to treat chronic pain, as without the
system there would be no basis for the effects of CBD.
Therapeutic Uses and Adjunct Therapy
For those patients who decided to try using CBD as a treatment for their chronic
pain, there are multiple different forms and ways that CBD can be used. CBD is most
widely considered as an addition to the use of other pain medications because, while
there is evidence to show that CBD is an effective treatment, there is not enough
evidence to show that CBD can be an effective standalone treatment for chronic pain
(Collins, 2020). Even though CBD may not be able to be the only medication
prescribed, there are many different forms of medication that a person can choose from
to use CBD as an adjunct therapy.
CBD is available in many forms, some of which include capsules, gummies,
tinctures, and topical creams (Hande, 2019). CBD has also been sold in oils, lotions,
bath bombs, masks, serums, toners, cosmetics, as well as massage oils. Some of the
most prescribed and used forms of CBD include pills, tinctures, syrups, and topical
preparations (Misuraca, 2020). These forms are some of the many different ways that
chronic pain patients can use CBD in their treatment. Since there is such a variety of
ways for patients to use CBD, there is not one standard dosage for treatment—
especially because patients will respond to CBD in different quantities (Tweed, 2019). If
patients are looking to treat joint and muscular pain, topical options are the most
appropriate since they can target the pain more directly and at the surface (Misuraca,
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2020). This same article explains that cannabinoids “have a biphasic effect, meaning
that low and high doses may produce opposite effects. More is not necessarily better,
so start with a moderate dose” (Misuraca, 2020, p. 26). These different articles point out
that there are multiple different ways to use and include CBD in a treatment plan for
chronic pain.
Legality
Even though there is evidence to show that CBD may be a beneficial tool in
treating patients with chronic pain, one of the largest obstacles is that marijuana and
hemp are both still considered controlled substances—making them illegal to use and
grow in the United States. In 1970, the Controlled Substances Act banned the growing
and selling of both hemp and marijuana. While federally marijuana is still illegal to grow
and sell in all capacities, hemp is now legal to grow as long as the plant contains less
than 0.3% THC with the passing of the 2014 Agricultural Act (VanDolah et al., 2019).
However, CBD is still considered to be a schedule I drug which means that, legally,
CBD cannot be bought or sold for medical purposes. However, 30 states and
Washington, District of Columbia. have legalized cannabis for medicinal use, even
though it remains illegal on a federal level (Hande, 2019). With federal guidelines in
place, though, CBD cannot technically be considered a medication that doctors can
prescribe their patients for pain.
Despite federal laws naming CBD to be a schedule I drug, other laws have been
passed to legalize CBD in some capacity. For example, “the US Hemp Farming Act of
2018 legalized the cultivation and refinement of hemp and its constituents, thus
beginning a trend of mass marketing for CBD products both legal and illegal” (Argueta
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et al., 2020, p. 2). CBD cannot be classified as legal in all 50 states, though, because
there are states that consider CBD to still be an illegal substance—despite the fact that
CBD is readily available in almost all states due to a lack of regulation (Hande, 2019).
The only officially legal source of CBD is a drug that is used to treat seizure activity,
Epidiolex, which is just purified CBD (Germano, 2018). As CBD remains a schedule I
drug, studies showing the potential of CBD to treat chronic pain effectively are fewer
due to legal issues surrounding these studies.
Lack of Purity
CBD is still considered to be a schedule I drug, which means that on a federal
level, CBD is completely illegal to buy or sell. In spite of some states’ new laws
considering cannabis and CBD to be legal in their states, however, the regulation of
CBD remains virtually non-existent. To demonstrate this, a study was done in 2017 that
showed the results of this lack of regulation on CBD products: “of 84 online CBD and
hemp oil products examined, only 26 were accurately labeled for CBD and THC
content, with CBD often being overlabeled and THC underlabeled” (VanDolah et al.,
2019, p. 1847). There have also been cases of THC toxicity in children as they are
ingesting THC from mislabeled CBD products (VanDolah et al., 2019). In order to verify
that the CBD product used is a quality product, there needs to be third-party testing
done to ensure that the label is correct. Testing has shown that there are often
contaminants in CBD products, including pesticides, heavy metals, and residual
solvents (Wait, 2019). These issues make finding a CBD product of high quality difficult,
and there is an obvious need for more regulation.
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Despite the lack of regulation, finding a quality CBD product is possible. In order
to find a safe product, a person should look for a full- or broad-spectrum product—these
contain more beneficial cannabinoids. It is important that the product has been tested by
a third-party lab, and, typically, buying CBD products that are organic tend to be safer
options (Armour, 2020). There are other aspects to consider as well. For example,
finding products that are imported from Europe may be beneficial as those products
have more strict guidelines on how much THC can be in a CBD product. Finding
products that are free from carbon dioxide and extraneous solvents would be beneficial
(VanDolah et al., 2019, p. 1847). There is also a nonprofit called Realm of Caring that
works closely with doctors, hospitals, and universities to compile a list of safe products,
which can be found on their website (Wait, 2019). Even though regulation of CBD
products is not closely monitored, finding a safe and quality product is still possible.
Adverse Effects and Interactions
CBD is a naturally occurring product and does not have psychoactive properties,
but, as with any medication, that does not mean there are not adverse effects and drug
interactions that still take place. In the larger studies, the most obvious side effects were
“somnolence, decreased appetite, and diarrhea noted in up to 30% of patients,” but the
side effects that are associated with the use of CBD were less severe than the ones
associated with other medications used to treat chronic pain (VanDolah et al., 2019, p.
1846-1847). Other side effects that have been noted include drowsiness, mild anxiety,
and nausea (Armour, 2020). Lastly, the side effects seen in this patient population
group were fatigue, diarrhea, dry mouth, and changes in appetite and weight—all of
which were pretty similar to the side effects seen in other patient populations (Corroon &
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Felice, 2019). While these side effects can certainly be unpleasant, CBD has a lower
adverse effect profile than many of the drugs that are used to treat chronic pain
(Corroon & Felice, 2019). Since CBD has fewer adverse effects, the appeal to use this
medication as an option in treating chronic pain is more desirable than some of the
other medications used for this purpose.
While most of the adverse effects are mild in comparison with those of other
chronic pain medications, there are several serious interactions with other drugs that
can occur. Naturally-occurring cannabinoids are non-psychoactive and can be used for
natural medicine; however, synthetic cannabinoids are being introduced to the market
and are quite dangerous as they often contain long-acting anticoagulant rodenticides
that can be damaging (Argueta et al., 2020). Another dangerous interaction is between
CBD and antiepileptic drugs, and, if patients are taking both of these medications,
doctors and nurses need to monitor for toxicity levels and adjust accordingly (Hande,
2019). Lastly, CBD interacts with the body in a similar way to grapefruit (juice) and
“inhibits the cytochrome P450 system.” With this similarity, doctors and nurses should
monitor CBD with the use of blood thinners, specifically Coumadin, and the patient
should have their blood levels checked frequently to monitor for adverse reactions
(Poorman, 2019, p. 2). There are serious drug interactions that take place when a
patient is taking CBD and these interactions should be monitored closely.
Conclusion
With the research that has previously been done, CBD has been shown to be an
option for treatment for patient’s that are experiencing chronic pain. While CBD may not
be a standalone treatment for chronic pain, studies have shown that using CBD as an
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adjunct therapy will provide pain relief, decrease the amount of opioid medications that
a patient is taking, and improve overall quality of life. However, there are a minimal
amount of studies that have been done with this topic because CBD is still considered
to be a schedule I drug and, therefore, makes clinical studies difficult. With laws that
restrict the ability for more in-depth research to be done with CBD, there needs to be
more research in order to make a firmer causal relationship between CBD and the
minimization of chronic pain. Additionally, there is a lack of regulation on CBD products
because of the federal laws which makes products potentially dangerous to take. One
positive of using CBD products for pain is that there are typically fewer side effects
when using CBD than the alternative medications that chronic pain patients are
prescribed.
Methodology
Design and Setting
The research method used for this study was a quantitative pre-test/post-test
design. In order to deliver an educational session and show the impact that the teaching
had on college students, a pre-test and post-test were used to understand the
advancement in knowledge. The pre-test and post-test contained only close-ended
questions.
The educational session was given as a one-time 30-minute session. The
session was conducted over Zoom and, in order to provide informed consent, the
participants first had to read through a cover letter (Appendix A) that explained the
purpose, their consent to participate, and how the data was going to be used in
research. Once the participants read through and decided to continue, they were able to
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proceed to the 13-question pre-test. The final two questions of the pre-test were
demographic questions, both of which included clauses regarding how these answers
were going to provide further information for research purposes. On average, the pretest took seven minutes for participants to complete. After the pre-tests were finished, a
20-minute educational session was given on the use of CBD for chronic pain, and the
primary aid was PowerPoint slides. After the educational session, the participants were
able to take the post-test through the link provided over Zoom. Questions for the test—
the same exact questions used in the pre-test—were developed from information
covered in the PowerPoint presentation which was based on up-to-date literature.
The effects of the intervention were determined through a paired t-test analysis of
the pre-test and post-test scores. The success of the research was determined by
whether there was statistical significance between the two tests. If the educational
session was successful, the statistical significance would support the use of an
educational session for educating patients on the use of CBD for chronic pain. If the
educational session was unsuccessful, the tests would indicate a need for alternative
methods for educating patients on the use of CBD for chronic pain.
The time and location for the session were determined by availability of the
researcher. The location of the session was via Zoom to keep participants and the
researcher safe since this took place during the COVID-19 pandemic. All the
information was collected anonymously by using a third-party survey website, and the
information was sent to an email related to the researcher. There was a random
drawing for three five-dollar gift cards to Murray Donuts for the participants who
attended. There was no extra credit given to any participants that attended.
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Materials
A 19-slide PowerPoint was prepared for the educational part of the study
(Appendix B). The PowerPoint focused on a variety of important aspects about the use
of CBD with chronic pain: how CBD is extracted, the variety of forms by which CBD can
be used, the significant data with CBD research, adverse effects, and how CBD
interacts with systems in the human body. The topics that were in the presentation and
also presented in the pre- and post-test included the different classifications of CBD,
adverse effects, the function of the endocannabinoid system, contraindications, and
chronic pain definition (Appendix C). The researcher had also developed a master copy
of the pre-test and post-test containing the correct answers for the questions (Appendix
D). Additionally, the demographic questions were present at the end of both the pre-test
and post-test.
The information used in the presentation came from a variety of sources. The
majority of the information used for the educational session came from Argueta et al.
(2020), Corroon and Felice (2019), and Hande (2019). There was additional
supplemental information that originated from the Drug Enforcement Administration
(2020) website, Pharmacology and the Nursing Process (2019), and a few other journal
articles. The materials used in the session included the following: a laptop, Zoom web
conferencing platform, a PowerPoint slide deck, and each individual’s laptop/desktop
with internet access.
Sampling Process
The sample included in the study was young adults attending Murray State
University. The objective of the sample selection was to focus on participants from a
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wide variety of disciplines in order to eliminate the possibility of bias, as students who
were in health-related fields would potentially have some information about the use of
CBD for pain. The researcher used convenience sampling by advertising to a specific
social organization of which she was a part. Other students also came to the session
from the use of flyers (Appendix E) and advertising of the educational session. The
focus of the study was on young adult students, so the desired range was 18-25 years
of age; students outside of that range could participate, but their data was not used.
Another method of advertising consisted of targeting honors students in their
residential college. The flyers were placed in Hollis C. Franklin Hall, which is the
residential college for Honors Students at Murray State University. In order to advertise
to students that were not a part of the residential college, the researcher sent out a
message to both a GroupMe and Facebook page that contained all members of the
Murray State social organization (Appendix F). Therefore, it can be assumed that all
participants who attended the educational session were members of Murray State
University. The participants attended the meeting voluntarily, with a random drawing of
three Murray Donuts at the end of the educational session.
Protection of Human Subjects
As this study did involve the use of human participants, Institutional Review
Board (IRB) approval was needed. An IRB application detailing the project significance,
participant selection, method of recruitment, methods of data collection, informed
consent process, plan for ensuring confidentiality and anonymity, and any conflicts of
interest was submitted for approval to Murray State University’s IRB on September 30,
2020. The IRB reviewed the study and found that it did not need IRB approval
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(Appendix G) and informed the researcher’s faculty member and researcher through
email on October 9, 2020. After the IRB’s decision, the researcher proceeded with the
study.
Before the participants began the pre-test and post-test, there was a cover letter
that identified the rights of the participants and that the participation in the study was
completely voluntary (Appendix A). Through the use of this cover letter, the participants
were given the choice on whether they wanted to participate, and they were informed
that they could leave at any time and not complete the study. Consent was implied if the
participant completed both the pre-test and post-test. If the participant did not complete
either the pre-test or post-test, this notified the researcher that the participant was
withdrawing from the study, and that data was not used.
In order to protect the anonymity of the participants, each individual that
completed the pre-test and post-test was provided the opportunity to pick a code name
that would not identify the participant. The participants were instructed to use the same
code name for both the pre-test and post-test. This allowed the researcher to compare
the pre-test scores and post-test scores without being able to identify the participants
who took part in the study. There was not a sign-up sheet or any way to connect the
code names to the participants that completed the study. Therefore, the researcher was
not able to match the code names to the participants. All of the results were kept strictly
confidential. Through this process, the anonymity and rights of all the participants were
protected.
Participants were informed that all data collected would be kept strictly
confidential and was only reviewed by the researcher and the researcher’s faculty
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member. No other individual was granted access to the information. The information
was stored on the researcher’s laptop which is password protected. As the information
is being kept on the researcher’s computer, the data is not being kept in a building on
campus. The results will be kept on the researcher’s password-protected computer for
five years before the results will be deleted.
Data Collection
At the beginning of the educational session, the researcher briefly explained the
study and the use of the research. The participants were then instructed to use the link
to take the pre-test. The link first had the cover letter appear, explaining the voluntary
nature of the study and the rights of the participants. The participants were then able to
click to the pre-test where they provided a code name to be used for both the pre-test
and post-test. At the end of the pre-test and post-test, there were two demographic
questions. One of the questions asked what gender the participant identified as and the
other question asked the participant with which race they identified. The pre-test and
post-test were then emailed to an email of the researcher.
To understand what the participants already knew about the use of CBD for
chronic pain, a pre-test was administered at the beginning of the educational session.
The method of testing involved a questionnaire using Survey Monkey. This allowed the
participants to take their time filling out the questionnaire using their own computers.
Each participant was asked eleven questions concerning the use of CBD and two
demographic questions. After the pre-test was completed, the PowerPoint presentation
over the use of CBD in the treatment and management of chronic pain was given. At the
completion of the PowerPoint presentation, a post-test was given that contained the
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same questions as the pre-test, including the two demographic questions (Appendix C).
After the post-test was completed, participants were allowed to leave the Zoom
meeting. The researcher waited until everyone left in case any participant had questions
or concerns about the research or educational session. Following the completion of the
post-test, the researcher organized the data through email and matched the pre-test
and post-test answers. The scores were then compared and statistically analyzed.
Results
There were 23 participants whose data was used in the results. Overall, there
was significant improvement between the pre-test and post-test. For the pre-test, the
mean of the correct answers was 5.83 out of 11, roughly 53%, and the standard
deviation was 1.67. The lowest score for the pre-test was 2/11 and the highest was
8/11. For the post-test, the mean of the correct answers was 10.2 out of 11, roughly
93%. This indicates that there was an overall increase of 40% between the first and
second tests. The standard deviation for the post-test was 1.24, which indicates that
there was less wide a spread of scores than the pre-test. The highest score on the posttest was 11/11 and the lowest score was 6/11. The increase of the group average from
the pre-test (53%) to the post-test (93%) illustrated a 40% increase between the scores.
Additionally, all participants scored 50% or higher on the post-test. This demonstrates
an increase in the understanding of the use of CBD on treatment of chronic pain. The
following graph shows the pre-test and post-test scores comparatively for each
participant. The x-axis is a number corresponding to each participant. The y-axis is the
number of questions, out of 11, that the participants got correct. The blue bar indicates
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the pre-test score of that participant. The orange bar indicates the post-test score of that
same participant.
Graph 1: Pre-test vs. Post-test Scores
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Each question was individually analyzed to compare the pre-test and post-test
results. These findings can be found in the following table which served as a tool of
evaluation:
Table 1: Question Analysis
Question/Topic

Pre-test Results

Post-test Results Increase/Decrease/No
Change

1

14/23 (60.9%)

22/23 (95.7%)

Increase +8 (57.1%)

2

22/23 (95.7%)

23/23 (100%)

Increase +1 (4.5%)

3

8/23 (34.8%)

22/23 (95.7%)

Increase +14 (175%)

4

9/23 (39.1%)

21/23 (91.3%)

Increase +12 (133%)
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5

10/23 (43.4%)

22/23 (95.7%)

Increase +12 (120%)

6

13/23 (56.5%)

21/23 (91.3%)

Increase +8 (61.5%)

7

18/23 (78.3%)

23/23 (100%)

Increase +5 (27.8%)

8

1/23 (4.3%)

18/23 (78.3%)

Increase +17 (1700%)

9

11/23 (47.8%)

21/23 (91.3%)

Increase +10 (90.9%)

10

22/23 (95.7%)

23/23 (100%)

Increase +1 (4.5%)

11

6/23 (26.1%)

19/23 (82.6%)

Increase +13 (216%)

The pre-test and post-test scores were analyzed through a paired t-test. After
statistically analyzing the results of each test, it was found that t=10.684 and the p value
<0.00001. The mean of the overall data collected was 4.39 and standard deviation of
1.97. The increase from the pre-test to the post-test was found to be statistically
significant as p<0.05. This indicates that the educational session on the use of CBD to
treat and manage chronic pain did have an impact on the post-test scores.
Demographics
There were some imbalances of demographics, especially considering the
ethnicity of the participants. Of the 23 participants, an overwhelming 21 were Caucasian
with one participant being Native Hawaiian or other Pacific Islander and another being
Hispanic or Latino. There was a gender imbalance as well, only 4/23 identified as male
and the remaining 19 identified as female.

23

Gender Distribution
17%

83%

Male

Female

Discussion
No individual performed worse on the post-test than they did on the pre-test.
Additionally, every participant performed better, at least by one point, on the post-test
than the pre-test. Through the statistical analysis of the results, the p-value for the tests
was found to be low (p<0.00001) and the t-value to be high (t=10.684). These results
indicate that the educational session contributed significantly to improving scores.
Therefore, the educational session can be considered a success for increasing the
scores between the pre-test and post-test for the sample. These findings of the
research study support the hypothesis that hosting an educational session would
increase the knowledge about the use of CBD with chronic pain.
An interesting question to analyze, and the second most missed question of the
test, was Question 11. This question looks at the contraindications of using CBD—what
medications should not be taken while using CBD. Before the educational session, only
6/23 (26.1%) of participants answered the question correctly. Part of the reason why
could be that people who were not in a medical field did not know what “contraindicated”
meant. The question did not explain at all what contraindicated meant; so, if the
participant had no context, it would make this question even harder. After the
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educational session, 19/23 participants (82.6%) answered this question correctly. This
shows significant increase in the understanding of what medications can be taken with
CBD and which medications should not be used with CBD.
The most missed question for the pre-test was Question 8 which related to the
best way to find information on CBD products that are safe and reliable. Only one
participant (4.3%) answered this question correctly on the pre-test. For the post-test,
18/23 (78.3%) of participants answered this question correctly. While there is some
pretty obvious improvement from the pre-test to the post-test, Question 8 was still the
most missed question on the post-test. This shows that there is still a need for
improvement in the education of finding reliable CBD products for use. As mentioned
earlier, CBD products are not regulated federally, so there is difficulty in understanding
and figuring out how to find reliable products for patients to use in the treatment and
management of chronic pain.
According to an article by Wait (2019), there was, and still is, a serious problem
with finding CBD products that are reliable for the use of treating chronic pain. Many of
the products are mislabeled which can make a safe product difficult to find. Wait (2019)
describes the issue of not having enough reliable resources on where to buy safe
products. As the results of the pre-test and post-test scores were analyzed, it was
evident that, before the educational session, the majority of the participants also did not
know where to find safe products, as only 1/23 (4.3%) answered the question correctly.
However, as Wait’s (2019) information explaining the different ways to find safe and
reliable products was shared in the presentation, after the educational session 18/23
(78.3%) of participants answered the question correctly. This shows that through
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educating people about the different ways to find products, safe products can be used
for the treatment of chronic pain.
Question 4 and Question 5 concerned the adverse effects of using CBD in the
treatment of chronic pain. Question 4 concerned the adverse effects that the general
population might experience—general population being those that are not considered a
vulnerable population. Members of a vulnerable population, for example, would be
pregnant women, underage children, and the elderly. On the pre-test, 9/23 (39.1%) of
participants answered the question correctly, answering that diarrhea is an adverse
effect of using CBD that the general population might experience. On the post-test,
21/23 (91.3%) of participants answered this question correctly. This demonstrates that
the educational session was successful in improving the knowledge of what is
considered an adverse effect of CBD to the general population. Question 5 concerns
whether there are adverse effects seen specifically for patients who are pregnant. In the
pre-test, 10/23 (43.4%) of participants answered this question correctly, stating that
there are adverse effects seen when a pregnant patient uses CBD. On the post-test,
22/23 (95.7%) participants answered this question correctly. This shows that, again, an
educational session is also an effective method to teach people about the adverse
effects of using CBD in patients from vulnerable populations who experience chronic
pain.
According to Germano (2019), less than 13% of medical schools in the United
States teach their students about the endocannabinoid system, which means that the
general population is even less likely know about the endocannabinoid system as high
schools do not teach about this system. In the pre-test and post-test, Question 6 dealt
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with how the endocannabinoid system affects the human body. On the pre-test, 13/23
(56.5%) of the participants answered the question correctly, selecting that the function
of the endocannabinoid system is part of the stress/harm network. This would seem to
indicate that more than 13% of the general population has heard of and knows how the
endocannabinoid system functions in the human body. However, there was not an
answer selection for “I don’t know”, which means that participants could have randomly
selected an answer for that question. However, it would seem that more than 13% of
participants knew, in advance, what the function of the endocannabinoid system is.
Limitations
The main limitation of this study was the sample size. Convenience sampling
was used to recruit college students to the study from a social group that the researcher
is a part of. As there were only 23 participants, it may be difficult to generalize these
results to the rest of the college student population—not only at Murray State University
but to other college students across the nation.
Another major limitation of this study was that the sample population was
majority Caucasian females. The study had an overwhelming sample of females, and
the results of the pre-test and post-test may not be generalizable to a more diverse
population. In order to best compare the results to a more general population of college
students, a second study with a more equal distribution of gender and race would need
to be performed.
Finally, a major limitation in this study was the need to use Zoom for the
educational session in order to keep the researcher and participants safe during the
coronavirus pandemic. Teaching and educational sessions are more difficult over Zoom
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because the participants are likelier to be distracted and to pay less attention to the
content being presented. For example, one of the participants was applying makeup
during the Zoom educational session as it was seen in the window of that participants
Zoom screen. This shows that the participants may not be giving their full attention to
the educational session and, therefore, their lack of attention could impact in the results
of the post-test.
Recommendations for Future Studies
One recommendation for this study is to increase the number of participants. A
sample that contained more individuals with the same inclusion criteria would help to
generalize the results to a more representative population of young adults across the
nation. By replicating the study with a larger, more diverse population there would be a
better understanding of what young adults understand about the use of CBD on the
treatment and management of chronic pain. In a replication, the researcher should
continue to target young adults in college but attempt to get a more equal number of
males and females with more diversity in racial background, so the study represents the
larger population more effectively.
Another recommendation would to be to target the questions in the pre-test and
post-test to align with more general characteristics of the research. For example,
another study could have multiple questions that concern the legality of CBD and
multiple questions that concern what CBD is and how it is manufactured. This way the
pre-test and post-test could have categories that the researcher could see the areas
that the participants were already knowledgeable about and which areas need more
specific teaching. This would also increase the number of questions overall on the pre-
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test and post-test which would allow the researcher to see if the participants were
retaining the information being taught. By adding more questions and categories, the
researcher could figure out how to perfect an educational session to increase the
understanding of using CBD for the management and treatment of chronic pain.
Additionally, the researcher should add a question about whether the participants
have ever used CBD before for any reason. This will allow the researcher to know if the
participants have any background with using CBD for pain, depression, anxiety, or any
other reason that would give them experience with using CBD. This would also give the
researcher information of how well a participant that does use CBD knows why and how
the CBD interacts with the human body. Occasionally, patients will take medication
without knowing the effects of the medication on the human body, so gaining this
information would allow the researcher to educate patients on topics that are more
indicated.
Another recommendation would be to use a different collection form. Using
SurveyMonkey is an easy way for the participants to take the pre-test and post-test over
Zoom because the participants can click on the link through the chat function. However,
the pre-test and post-test asked the participants to enter a code name in order to help
with the anonymity of the study. Because of the nature of the educational session, the
survey relied on the participants to read and add their code name on their own.
However, not all the participants added a code name, which made those results
incapable of being used for the study. This was done in order to keep the anonymity
and confidentiality of the participants. If there was a replication of the educational
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session, using a different collection method or being able to hold the session in person
would allow the anonymity and confidentiality to be stronger.
Finally, conducting a study that looked at the long-term effects of the educational
session would provide information on what content was retained and how well it was
retained over time. The post-test was given immediately after the educational session
was finished. However, the information that was learned in the educational session
could be forgotten over time after the educational session. Conducting another post-test
or study a year after the educational session would provide information about the
longevity of the educational session and how truly effective the session was.
Additionally, following up with the participants to see whether they have used CBD
products since the educational session would provide information on the how the
information was used in the participants’ lives. Conducting a survey about whether the
participants used CBD and for what they used it would provide information about what
the researcher could put in a future educational session.
Conclusion
The results of this study support the hypothesis that an educational session
would improve the understanding of the use of CBD in the treatment and management
of chronic pain in college students, specifically young adults at Murray State University.
Through the use of the pre-test, the participants’ current knowledge level about the use
of CBD for the management and treatment of chronic pain was evaluated. After the
educational session, there was a significant increase in the scores for the post-test. This
shows that an educational session may be a good way to deliver information about the
use of CBD for chronic pain. The findings of this study may be used for further teaching
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as well as to encourage patients to explore other options for the treatment of chronic
pain instead of just using highly addictive narcotics.
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Appendix A
Cover Letter Attached to Pre-test
Please Read before Completing Questionnaire
Invitation to Participate: You are being invited to participate in a research study entitled
Management and Treatment of Chronic Pain using CBD that is being conducted by
Emily Davis, an undergraduate nursing student at Murray State University. I want to
invite you to participate by filling out a questionnaire that will help me understand your
knowledge on the management and treatment of chronic pain using CBD. I am trying to
obtain information from my peers to understand what is known about CBD. Please
answer these questions to the best of your ability without the use of external materials.
Purpose & Participant Enrollment: If you agree to participate, you will be asked to fill out
a questionnaire about your knowledge of using CBD to treat and manage pain. The
questionnaire is compiled of 12 survey questions and should take no more than 12
minutes to complete.
Risks & Benefits: There are no foreseeable risks to participating in the research. The
direct benefits to you are minimal, but I do think the study will make a contribution to
Healthcare awareness.
Voluntary Participation: Your participation in this study is completely voluntary. You
have a right to refuse to participate without consequences or discontinue your
participation at any time without penalty. You may refuse to answer any specific
questions at any time during the survey. Withdrawal or refusing to answer specific
questions will not result in any consequences to you. If you agree to be a part of the
research, but later change your mind, you may stop at any time.
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Data: If you agree to participate, your responses will be anonymous. I do not collect
identifying information such as your name. Should you choose to respond, I will keep
your information confidential, such as your answers and returning email address, by
storing all results in my personal password protected computer accessible only to
myself, the primary investigator. To help protect your confidentiality, the survey will not
contain information that will personally identify you. The results of this study will be used
for scholarly purposes only.
If you have any questions or concerns about the research study, please contact my
faculty mentor, Dr. Jessica Naber, at jnaber@murraystate.edu
Your completion of this questionnaire will indicate your voluntary consent for
participation in this research study.
This study has been reviewed and approved by the Murray State University Institutional
Review Board (IRB) for the protection of human research participants. Any questions
about the conduct of the study should be addressed to Dr. Jessica Naber, 270-8096690, jnaber@murraystate.edu. Any questions about your rights as a research
participant should be addressed to the IRB Coordinator at 270-809-2916,
msu.irb@murraystate.edu
Thank you,
Emily Davis
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Appendix B
CBD Educational Session PowerPoint Presentation
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Appendix C
Pre-test/Post-test Questions (Blank)
1. What is the main difference between THC and CBD?
a. Different schedules of drugs according to the DEA
b. In which plant the component is stored
c. One is psychoactive and the other is not
d. In which system the component reacts with
2. True or False: CBD has medically significant action in reducing pain.
a. True
b. False
3. What schedule is CBD classified as?
a. Schedule I
b. Schedule II
c. Schedule III
d. Schedule IV
4. What is an adverse effect of using CBD?
a. Heavy Metal contamination
b. Cancer
c. Diarrhea
d. Bleeding
5. True or False: CBD is not known to cause problems in pregnancy.
a. True
b. False
6. What is a function of the Endocannabinoid system in the body?
a. Breakdown of food into smaller components
b. Stress/Harm Regulation Network
c. Protects the organism from its surroundings
d. Receive information and generate a response
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7. What is a product through which CBD can be absorbed into the body?
a. IV
b. Topical cream
c. Lozenge
d. Eye Drops
8. Which website provides you with information of reliable sources of CBD?
a. Drugs.com
b. Webmd.com
c. Fda.gov
d. Theroc.us
9. How long does pain have to be present to be considered chronic pain?
a. 2 days
b. 2 weeks
c. 2 months
d. 6 months
10. True or False: Research on CBD is complete.
a. True
b. False
11. Which is a contraindication of using CBD?
a. Arthritis Medication
b. Caffeine
c. Oral contraceptives
d. Antibiotics
12. For the purpose of analyzing this data in different ways, please identify your
racial category.
a. Asian or Asian American
b. Black or African American
c. Hispanic or Latino
d. White or Caucasian
e. American Indian or Alaska Native
f. Native Hawaiian or other Pacific Islander
g. Other (please specify)
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13. For the purpose of analyzing this data in different ways, please choose the
answer that conveys how you identify your gender:
a. Male
b. Female
c. Genderqueer/Non-binary
d. Other (please specify)
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Appendix D
Pre-test/Post-test (Answers)
1. What is the main difference between THC and CBD?
a. Different schedules of drugs according to the DEA
b. In which plant the component is stored
c. One is psychoactive and the other is not
d. In which system the component reacts with
2. True or False: CBD has medically significant action in reducing pain.
a. True
b. False
3. What schedule is CBD classified as?
a. Schedule I
b. Schedule II
c. Schedule III
d. Schedule IV
4. What is an adverse effect of using CBD?
a. Heavy Metal contamination
b. Cancer
c. Diarrhea
d. Bleeding
5. True or False: CBD is not known to cause problems in pregnancy.
a. True
b. False
6. What is a function of the Endocannabinoid system in the body?
a. Breakdown of food into smaller components
b. Stress/Harm Regulation Network
c. Protects the organism from its surroundings
d. Receive information and generate a response
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7. What is a product through which CBD can be absorbed into the body?
a. IV
b. Topical cream
c. Lozenge
d. Eye Drops
8. Which website provides you with information of reliable sources of CBD?
a. Drugs.com
b. Webmd.com
c. Fda.gov
d. Theroc.us
9. How long does pain have to be present to be considered chronic pain?
a. 2 days
b. 2 weeks
c. 2 months
d. 6 months
10. True or False: Research on CBD is complete.
a. True
b. False
11. Which is a contraindication of using CBD?
a. Arthritis Medication
b. Caffeine
c. Oral contraceptives
d. Antibiotics
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Appendix E
Flyer Advertising Educational Session
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Appendix F
Message for Advertisement on Facebook and GroupMe
Hey, guys!!
I know I have talked to some people about this, but tomorrow, Wednesday 10/21, at 6
pm I am presenting my research for my thesis in an educational session over zoom!
I need people to come because I have a pre-test and post-test that I will need to
incorporate into my thesis!
My research is over the management and treatment of chronic pain using CBD and the
actual presentation part should be pretty short and sweet.
I am going to add the link and if people could make it and would come that would be so
amazing and helpful!!! Also, there is a drawing for three Murray Donuts gift cards if you
attend!!
Topic: Emily Davis' Personal Meeting Room
Join Zoom Meeting
https://murraystate.zoom.us/j/7015415923…
Meeting ID: 701 541 5923
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Appendix G
IRB Exemption Letter

TO: Jessica Naber, Nursing
FROM: Jonathan Baskin, IRB Coordinator
DATE: October 9, 2020
RE: Determination for IRB # 21‐033
Project Title:The Management and Treatment of Chronic Pain Using CBD
Principal Investigator(s): Emily Davis
Determination: Quality Improvement/Assessment ‐ Activity is not research as defined in 45 CFR
46.102(l)
The Murray State University IRB has reviewed the information you supplied for the project named
above. Based on that information, it has been determined that this project does not involve activities
and/or subjects that would require IRB review and oversight. The IRB will keep your determination form
on file for a period of 3 years.
Please note that there may be other Federal, State, or local laws and/or regulations that may apply to
your project and any changes to the subjects, intent, or methodology of your project could change this
determination. You are responsible for informing the IRB of any such changes so that an updated
determination can be made. If you have any questions or require guidance, please contact the IRB
Coordinator for assistance.

Thank you for providing information concerning your project.

